Identifying B7-H3 and LAG3 as surface molecules expressed on CD4 CTLs with enhanced cytotoxic potential may provide new opportunities for manipulating CD4+ T cells in T cell therapies for B-ALL and other HLA class II-expressing tumors. Here, CD4 is linked to precursor B-cell acute lymphoblastic leukemia.